Immunomod

Management Team

Dr. Key is currently Chair of the Department of Pediatrics at the Medical University of South Carolina (MUSC), and Physician-in-Chief at MUSC's Children's Hospital. Dr. Key completed his fellowship in 1983 at the Children's Hospital in Boston, where he trained in diabetes with Dr. Ken Gabbay, Dr. Lori Laffel, Dr. Gordon Wier, and Dr. Josheph Wolfsdorf. He has been active in diabetes care since his residency at Duke University where he was the first physician to use split/mixed insulin in new onset diabetes pediatric patients. He also introduced the use of insulin drips for the treatment of DKA. He has managed over 1500 new onset diabetics during his career at Children's Hospital, Bowman Gray Medical School (Wake Forest University), and MUSC. At MUSC, he spearheaded a drive to complete an islet cell isolation facility that came on line in 2003. Dr. Key has worked with Dr. Inderjit Singh to move animal studies into practice. Dr. Key conceived of a trial of statins for treating MS. He held the IND for this project and was the PI on the Merck Grant that supported this successful project. Diabetes studies in NOD mice were begun by Dr. Key and Dr. Singh to provide a basis for investigation of suppressing the release of pro-inflammatory cytokines in immune mediated (Type 1) diabetes. Dr. Key is a co-author on a paper resulting from a study that he conceived that detailed the effects of glucose on iNOS, resulting in islet cell toxicity. Dr. Key has experience with multiple INDs and has taken an IND from the bench to an FDA approval. Dr. Key has raised over $25 million through federal and non-profit sources. He has over 25 years of clinical trial experience with such institutions as Harvard Medical School, Wake Forest, MUSC, Genentech, TAP Pharmaceuticals, Merck, and Pfizer.

Dr. Singh is Professor of Pediatrics and Scientific Director of the Children's Research Institute at the Medical University of South Carolina (MUSC). Dr. Singh obtained his BS and MS in Biochemistry at Punjab University in India, and his Ph.D. in Biochemistry at Iowa State University. After graduation, he was a post-doctoral Research Fellow at the Eunice Kennedy Shriver Center for Mental Retardation, Department of Neurology, Massachusetts General Hospital in Boston, MA. Following his fellowship, Dr. Singh was an Associate Professor, Department of Neurology, at Johns Hopkins School of Medicine in Baltimore, MD. In 1984 Dr. Singh joined the faculty in the Pediatric Department at MUSC where he is currently the Director of the Division of Developmental Neurogenetics, Vice Chairman of Research, and Scientific Director of the Children's Research Institute. His most recent endeavors invole the childhood disorders of neonatal hypoxia/ischemia, spinal cord injury, cerebral palsy, inherited metabolic disorders, and type 1 diabetes. Dr. Singh is credited for the development of therapeutics for some of these disorders. In fact, his laboratory was the first to identify statins as anti-inflammatory drugs.

Mr. Faith has founded and successfully grown numerous companies throughout the course of his career. He has raised and invested over $2.5 Billion from major financial institutions, government pension funds, public equity markets, and private investors. He has served as Chief Executive Officer of both private and public companies, and has a successful track record running an institutional investment company. Mr. Faith co-founded Starwood Capital Partners, which he grew and subsequently sold. He also founded Homegate Hospitality, which he took public (NASDAQ: HMGT), and EdenCare Assisted Living, which was acquired. Mr. Faith is currently Chief Executive Officer and Chairman of Greystar, a premier investment and services company in the real estate industry, which he founded in 1993. He also heads Faith Family Holdings, an investment company in Charleston, SC. From 2002-2006, Mr. Faith served as the Secretary of Commerce for the State of South Carolina, where under his leadership, the state created more jobs than any other administration in history. While at the State, Mr. Faith helped initiate and approve the Venture Capital Investment Act of South Carolina, which will expand the funding opportunities of emerging technology and biotechnology companies in the State. Mr. Faith received his B.S. degree from Oklahoma University, and his M.B.A. degree from Harvard Business School. The catalyst for Mr. Faith's connection with Dr. Key and Dr. Singh was his daughter's development of Type 1 diabetes.